SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-22-001792
Filing Date
2022-05-19
Accepted
2022-05-19 17:15:42
Documents
66
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q scps-20220331x10q.htm   iXBRL 10-Q 855664
2 EX-31.1 scps-20220331xex31d1.htm EX-31.1 17369
3 EX-31.2 scps-20220331xex31d2.htm EX-31.2 17509
4 EX-32.1 scps-20220331xex32d1.htm EX-32.1 8195
5 EX-32.2 scps-20220331xex32d2.htm EX-32.2 8092
  Complete submission text file 0001410578-22-001792.txt   4121253

Data Files

Seq Description Document Type Size
6 EX-101.SCH scps-20220331.xsd EX-101.SCH 49047
7 EX-101.CAL scps-20220331_cal.xml EX-101.CAL 22308
8 EX-101.DEF scps-20220331_def.xml EX-101.DEF 166164
9 EX-101.LAB scps-20220331_lab.xml EX-101.LAB 361712
10 EX-101.PRE scps-20220331_pre.xml EX-101.PRE 284121
60 EXTRACTED XBRL INSTANCE DOCUMENT scps-20220331x10q_htm.xml XML 442359
Mailing Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170 (212) 479-2513
Scopus BioPharma Inc. (Filer) CIK: 0001772028 (see all company filings)

IRS No.: 821248020 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39788 | Film No.: 22944148
SIC: 2834 Pharmaceutical Preparations